NAYZILAM® (midazolam) nasal spray, CIV, gets extended shelf life approval The U.S. Food and Drug Administration has reviewed new drug stability data from UCB, Inc. and approved an extended shelf life from 12 to 24 months for NAYZILAM — the first nasal spray approved for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Patients and caregivers prescribed NAYZILAM will now receive a product that reflects the extended expiration date of up to 24 months.
Learn More: Healthcare Professionals | NAYZILAM® (midazolam) nasal spray, CIV
SOAR Webinar
**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...
